Rituximab常见分子靶向药物的分类.PPT

常见分子靶向药物的分类 常见分子靶向药物的分类（续） First, let us look at the adjuvant therapy in pancreatic cancer. At the present moment, surgical resection is still the only treatment that can offer cure to patients with Ca pancreas. However, only a small proportion of patients get cure as evidenced by around 5 yr survival rate as low as 10%. As most of you and investigators might be aware, adjuvant therapy is important to potentially improve the outcome of such a deadly disease. Comments. When we take of look of the survival figures between clinical trials, you can see for surgery alone, the 5 yrs survival rate is ~10% (which is signifying cure in ca pancreas). but in the presence of adjuvant chemo, the 5 yr survival rate has improved to 20% in chemo arm in ESPAC-1 and CONKO-01, In current ESPAC-3 study, the results further consolidate the benefits of adjuvant chemotherapy with very similar figure to the chemo arm of previous trials, meaning that the adjuvant chemotherapy could help cure some of the patients. Remember that the 5yr survival rate means cure in patients with Ca pancreas. The ESPAC-3 plays an important role that it further reproduce such survival data. Another crucial findings from ESPAC-3 is that it confirms the prognostic factors namely grading, staging and quality of resection. However, I have to say that this is a negative study. This study is initially designed to domonstrate the superiority of gem over 5FU/FA. But it fails to. Hence it wont help us change the practice too much…but there is some provocative points that there is a trend favoring gemcitabine in terms of toxicity profile and R1 patients. * Comments. When we take of look of the survival figures between clinical trials, you can see for surgery alone, the 5 yrs survival rate is ~10% (which is signifying cure in ca pancreas). but in the presence of adjuvant chemo, the 5 yr survival rate has improved to 20% in chemo arm in ESPAC-1 and CONKO-01, In current ESPAC-3 study, the results further consolidate